GPhA Asks FDA To Create Task Force On Generic Biopharmaceuticals
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency should abandon its “arbitrator” role in the face of the brand industry’s continued reluctance to discuss a path forward, GPhA maintains. FDA should put together an analysis of the issues to be presented at an upcoming FDA/DIA meeting.
You may also be interested in...
GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
BIO Comments On Follow-On Biologics Will Include Manufacturing Anecdotes
FDA officials' questions to industry reps during public workshop focus on the level of studies that should be required for follow-on biologic applications, particularly in comparison to requirements for manufacturing process changes by innovators.